Viewing nowIgitin Tablet 20mg (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Huson Co., Ltd.

MFDS item code 202302992 · Approved 2023.10.26 · Insurance code 670609200
Treatment of moderate to severe Alzheimer's disease
This medication is used to treat moderate to severe Alzheimer's disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver can periodically check that the patient is taking the medication. The diagnosis should be made in accordance with currently accepted guidelines. The clinical benefit of this medication and the patient's tolerance of treatment should be reassessed periodically. This medication is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. This medication may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1-7) Administer 5mg once daily for 7 days. Week 2 (Days 8-14) Administer 10mg once daily for 7 days. Week 3 (Days 15-21) Administer 15mg once daily for 7 days. From Week 4 onward Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years and over is 20mg once daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg once daily in accordance with the standard dose escalation method after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medication.
This medication should not be used in patients with a hypersensitivity to its ingredients. Patients with severe liver or kidney damage should also not take this medication. Patients with epilepsy or those who have experienced seizures in the past should use this medication cautiously. Particularly, the concurrent use of certain medications such as amantadine, ketamine, and dextromethorphan may exacerbate central nervous system side effects, and thus should be avoided. Patients with situations that alter urine acidity (pH) should be observed closely. Due to insufficient safety data, this medication should be used cautiously in patients with heart disease or uncontrolled hypertension. Side effects such as dizziness, headaches, constipation, drowsiness, and high blood pressure may occur; if symptoms are severe, consult a doctor. Additionally, symptoms like mental confusion or hallucinations may rarely occur; report any unusual symptoms immediately. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking other medications. Caution is especially required when used concurrently with antipsychotics, skeletal muscle relaxants, and anticoagulants. Women who are pregnant or may become pregnant should consult a doctor before taking this medication, and nursing mothers are advised to discontinue breastfeeding. The safety and efficacy of this medication in children under 18 years of age have not been established. In cases of overdose, serious symptoms such as coma, hallucinations, or seizures may occur, so seek medical attention immediately; there is no specific antidote, and treatment will be symptomatic. This medication can affect patient concentration and reaction speed, so use caution when driving or operating machinery. Finally, this medication must be stored out of reach of children and should not be transferred into another container.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it is important to store it at a temperature between 1 and 30 degrees Celsius to maintain efficacy.
Pink oval film-coated tablet
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Huson Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.